Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially starve tumor cells and enhance immune-cell activity. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients.
Location: United States, California, South San Francisco
Employees: 51-200
Total raised: $77.4M
Founded date: 2010
Investors 4
| Date | Name | Website |
| - | Mission Bi... | missionbio... |
| - | Lightstone... | lightstone... |
| - | Delphi Ven... | delphivent... |
| - | New Leaf V... | nlvpartner... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 02.11.2020 | - | $2.4M | - |
| 29.10.2013 | Series D | $35M | - |
| 08.07.2010 | Series A | $40M | - |
Mentions in press and media 9
| Date | Title | Description |
| 29.03.2022 | Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock and Warrants to Purchase Common Stock | SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that it intends to offer and sell shares of its comm... |
| 18.10.2021 | Calithera Biosciences : Investor Deck | Targeting cancer, differently. Susan M. Molineaux, Ph.D. | Founder, President & Chief Executive Officer NASDAQ: CALA CALITHERA® and the Calithera Logos are trademarks or registered trademarks of Calithera Biosciences, Inc. All rights re... |
| 17.05.2021 | Antengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708 (ATG-037) | SHANGHAI and SOUTH SAN FRANCISCO, Calif., May 17, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commerciali... |
| 02.11.2020 | Calithera Biosciences receives a $2.4M funding award from the CF Foundation to advance a potential treatment to reduce infections in the lungs of people with cystic fibrosis | Calithera Biosciences is a San Francisco-based clinical-stage biopharmaceutical company pioneering the discovery and development of targeted, small-molecule therapies that disrupt cellular metabolic pathways to preferentially block tumor ce... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 29.10.2013 | UPDATED: Calithera grabs $35M round to fund first slate of cancer drug studies | Calithera Biosciences CEO Susan Molineaux South San Francisco-based Calithera Biosciences has landed a $35 million round that will be largely earmarked to fund its first clinical cancer drug program. Led by Susan Molineaux--who helmed Prote... |
| 29.10.2013 | Calithera Biosciences Completes $35M Series D Financing | Calithera Biosciences, a South San Francisco, CA-based biotechnology company focused on the development of novel cancer therapeutics, completed a $35m Series D financing. The round was led by Adage Capital Partners, LP., with participation ... |
| 29.10.2013 | Calithera Biosciences Secures $35Min Series D | SOUTH SAN FRANCISCO, CA, Biotechnology company focused on the development of novel cancer therapeutics, today announced the successful completion of a $35 million Series D financing. >> Click here for more funding data on Calithera... |
| 08.07.2010 | Calithera Biosciences Completes $40M Series A Financing | Calithera Biosciences, a South San Francisco, CA-based developer of innovative oncology therapeutics, has completed a $40m Series A financing. The round was led by Morgenthaler Ventures, with participation from U.S. Venture Partners, Advanc... |